![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
References
- Silberstein SD, for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754–62
- International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: 2nd edn. Cephalalgia 2000;20:765–86
- Dowson AJ, Lipscombe S, Sender J, et al. New guidelines for the management of migraine in primary care. Curr Med Res Opin 2002;18:414–39
- Lipscombe S, Rees T Dowson AJ. Tailoring migraine management in primary care to the needs of the individual patient. Headache Care 2004;1:147–57
- Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668–75
- Belsey JD. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. J Clin Res 2001;4:105–27
- Loder E, Brandes JL, Silberstein S, et al. Preference comparison of rizatriptan ODT 10mg and sumatriptan 50mg tablet in migraine. Headache 2001;41:745–53
- Pascual J, Munoz R, Leira R. An open preference study with sumatriptan 50mg and zolmitriptan 2.5mg in 100 migraine patients. Cephalalgia 2001;21: 680–4
- Dowson AJ, Sender J, Lipscombe S, et al. Establishing principles of migraine management in primary care. Int J Clin Pract 2003;57:492–507
- Lipton RB, Goadsby PJ, Sawyer JPC, et al. Migraine: diagnosis and assessment of disability. Rev Contemp Pharmacother 2000;11:63–73
- Lofland JH, Kim SS, Batenhorst AS, et al. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc 2001;76:1093–101
- Coukell AJ, Lamb HM. Sumatriptan: a pharmacoeconomic review of its use in migraine. Pharmacoeconomics 1997;11:473–90
- Savani N, Martin A, Browning D. Switching patients with migraine from sumatriptan to other triptans increases primary care costs. Int J Clin Pract 2004;58:758–63
- Williams D, Cahill T, Dowson A, et al. Usage of triptans among migraine patients: an audit in nine GP practices. Curr Med Res Opin 2002;18:1–9
- Auriacombe S, Pere J-J, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18:129–138
- Bullock R, Connolly C. Switching cholinesterase inhibitor therapy in Alzheimer's disease – donepezil to rivastigmine, is it worth it? Int J Geriatr Psychiatry 2002;17:288–9
- Stark S, Spierings EL, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000;40:513–20